R F Slykerman1, C Coomarasamy2, K Wickens3, J M D Thompson2, T V Stanley4, C Barthow3, J Kang3, J Crane3, E A Mitchell2. 1. Department of Psychological Medicine, University of Auckland, Private Bag 92019, Auckland, 1142, New Zealand. r.slykerman@auckland.ac.nz. 2. Department of Paediatrics: Child and Youth Health, University of Auckland, Private Bag 92019, Auckland, 1142, New Zealand. 3. Department of Medicine, University of Otago, P O Box 7343, Wellington, New Zealand. 4. Department of Paediatrics, University of Otago, P O Box 7343, Wellington, New Zealand.
Abstract
RATIONALE: Antibiotics are commonly prescribed for infants. In addition to increasing concern about antibiotic resistance, there is a concern about the potential negative impact of antibiotics on the gut microbiota and health and development outcomes. OBJECTIVE: The aim of this study was to investigate the association between early life antibiotic exposure and later neurocognitive outcomes. METHODS: Participants were infants born to mothers enrolled in the probiotics study. The initial study was designed to evaluate the effect of two different probiotics on allergy outcomes in childhood. Antibiotic exposure was based on parent report and categorised according to the following timing of the first exposure: 0-6 months, 6-12 months, 12-24 months or not at all. At 11 years of age, children's neurocognitive outcomes were assessed using psychologist-administered, parent-report and self-report measures. The relationship between the timing of antibiotic exposure and neurocognitive outcomes was examined using regression models. RESULTS: Of the 474 participants initially enrolled, 342 (72%) children had a neurocognitive assessment at 11 years of age. After adjustment for mode of delivery, probiotic treatment group assignment, income and breastfeeding, children who had received antibiotics in the first 6 months of life had significantly lower overall cognitive and verbal comprehension abilities, increased risk of problems with metacognition, executive function, impulsivity, hyperactivity, attention-deficit hyperactivity disorder, anxiety and emotional problems. CONCLUSIONS: These results provide further evidence that early exposure to antibiotics may be associated with detrimental neurodevelopmental outcomes.
RATIONALE: Antibiotics are commonly prescribed for infants. In addition to increasing concern about antibiotic resistance, there is a concern about the potential negative impact of antibiotics on the gut microbiota and health and development outcomes. OBJECTIVE: The aim of this study was to investigate the association between early life antibiotic exposure and later neurocognitive outcomes. METHODS:Participants were infants born to mothers enrolled in the probiotics study. The initial study was designed to evaluate the effect of two different probiotics on allergy outcomes in childhood. Antibiotic exposure was based on parent report and categorised according to the following timing of the first exposure: 0-6 months, 6-12 months, 12-24 months or not at all. At 11 years of age, children's neurocognitive outcomes were assessed using psychologist-administered, parent-report and self-report measures. The relationship between the timing of antibiotic exposure and neurocognitive outcomes was examined using regression models. RESULTS: Of the 474 participants initially enrolled, 342 (72%) children had a neurocognitive assessment at 11 years of age. After adjustment for mode of delivery, probiotic treatment group assignment, income and breastfeeding, children who had received antibiotics in the first 6 months of life had significantly lower overall cognitive and verbal comprehension abilities, increased risk of problems with metacognition, executive function, impulsivity, hyperactivity, attention-deficit hyperactivity disorder, anxiety and emotional problems. CONCLUSIONS: These results provide further evidence that early exposure to antibiotics may be associated with detrimental neurodevelopmental outcomes.
Authors: Yuliya E Borre; Gerard W O'Keeffe; Gerard Clarke; Catherine Stanton; Timothy G Dinan; John F Cryan Journal: Trends Mol Med Date: 2014-06-20 Impact factor: 11.951
Authors: G Clarke; S Grenham; P Scully; P Fitzgerald; R D Moloney; F Shanahan; T G Dinan; J F Cryan Journal: Mol Psychiatry Date: 2012-06-12 Impact factor: 15.992
Authors: Eleni Angeli; Terpsichori Korpa; Elizabeth O Johnson; Filia Apostolakou; Ioannis Papassotiriou; George P Chrousos; Panagiota Pervanidou Journal: Psychoneuroendocrinology Date: 2018-02-23 Impact factor: 4.905
Authors: Alexander L Carlson; Kai Xia; M Andrea Azcarate-Peril; Barbara D Goldman; Mihye Ahn; Martin A Styner; Amanda L Thompson; Xiujuan Geng; John H Gilmore; Rebecca C Knickmeyer Journal: Biol Psychiatry Date: 2017-06-27 Impact factor: 13.382
Authors: Christopher Harshaw; Sayuri Kojima; Cara L Wellman; Gregory E Demas; Ardythe L Morrow; Diana Hazard Taft; William M Kenkel; Joseph K Leffel; Jeffrey R Alberts Journal: Dev Psychobiol Date: 2022-09 Impact factor: 2.531
Authors: Lucy McDonnell; Alexander Gilkes; Mark Ashworth; Victoria Rowland; Timothy Hugh Harries; David Armstrong; Patrick White Journal: Gut Microbes Date: 2021 Jan-Dec